As studies increasingly correlate SMARCA4 with lung cancer treatment and prognosis, the accurate identification of SMARCA4-deficient tumor subtype becomes critical and may necessitate specific therapeutic strategies. This evidence concerns the gene SMARCA4 and neoplasm.